COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The CDC issued revised guidance for pediatric clinicians on caring for newborns with confirmed or suspected COVID-19 or known COVID-19 exposure, including birth to a mother with confirmed or suspected COVID-19.
To facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation, the Food and Drug Administration approved the use of succinylcholine chloride injection USP 200 mg/10 mL.
The CDC has released a framework for providing non-COVID-19 clinical care during the pandemic, based on the level of community transmission and potential for patient harm from deferring in-person care.
CMS said that until Medicare sets national payment rates for COVID-19-related testing claims, its Medicare Administrative Contractors have authority to set payment amounts in their respective jurisdictions.
In response to the significant impact of the COVID-19 pandemic on nursing homes, the Centers for Medicare & Medicaid Services recommended criteria for state and local officials who are considering how to mitigate risks.
The CDC awarded $10.25 billion from the Paycheck Protection Program and Health Care Enhancement Act to states, territories and local jurisdictions, and $750 million to tribal health programs to expand COVID-19 testing capacity and related activities.
Infectious virus in feces is a common manifestation of COVID-19, according to a study from China published in the Center for Disease Control and Prevention’s Emerging Infectious Diseases journal.
The Food and Drug Administration authorized the emergency use of Everlywell, Inc.’s COVID-19 Test Home Collection Kit.
The Food and Drug Administration authorized the emergency use of infusion pumps to counteract insufficient supplies needed for the continuous infusion of medications, total parenteral nutrition and other fluids into COVID-19 patients.
Based on early data, the Abbott ID NOW point-of-care test to diagnose COVID-19 may return false negative results, the Food and Drug Administration announced, adding that it will continue to review data as the company conducts post-market studies to better understand the cause.